Multicentric Oncologic Outcomes of High-Intensity Focused Ultrasound for Localized Prostate Cancer in 803 Patients

High-Intensity Focused Ultrasound (HIFU) - An Alternative Choice in Prostate Cancer Treatment

“…One of the most recent is the multicentric study carried out by Crouzet et al 16 , who reported a series of 803 patients with a mean follow-up of 43 months. The results of this study are excellent, showing that local control and disease-free survival rate achieved with HIFU were similar to those expected with conformal external-beam radiation therapy (EBRT).…”

Correlation of pretreatment clinical parameters and PSA nadir after high-intensity focused ultrasound (HIFU) for localised prostate cancer

“…Uchida and associates reported that in patients with a PSA nadir of 0.0-0.2 ng/ml, treatment failure rate based on positive biopsies was 11 % compared with 46 % in those with a PSA nadir of 0.21-1.00 ng/ml and 48 % (20/42) with a PSA nadir of >1.0 ng/ml [12]. Similarly, a PSA nadir of ≤0.3 ng/ml was associated with a BDFSR of 84 % at 7 years compared with 51 and 35 % for nadirs of 0.31-1.0 and >1 ng/ml, respectively [14]. Five-year BDFSR was reported to vary according to PSA nadir with rates of 84, 64, 40 and 30 % for PSA nadirs of ≤0.2, 0.21-0.5, 0.51-1.0 and >1 ng/ml, respectively [13].…”

“…Disease-free survival rates (DFSRs) reported with HIFU include 5-year rates of 66 % [8] and 81 % [9], a 7-year rate of 59 % [10] and a 10-year rates of 60 % [11] and 61 % [9]. PSA nadir following HIFU has been correlated with oncologic outcome in a number of studies, suggesting that nadirs of <0.2 [12,13] or ≤0.3 ng/ ml [14] were associated with improved outcome.…”

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

“…Blana et al [13•] also reported an 8-year experience of 163 patients in Germany (T1-2, N0M0, PSA ≤20 ng/mL, Gleason ≤7) followed for 4.8±1.2 years and observed a 5-year biochemical survival rate of 75%. More recently, Crouzet et al [14] reported a multicenter analysis consisting of 803 patients from six French centers followed for 42 ±33 months. They observed 5-and 7-year biochemical survivals according to the Phoenix definition of 83% and 75%, respectively, for the low-risk group and 72% and 63%, respectively, for the intermediate-risk group.…”